148 related articles for article (PubMed ID: 38619193)
1. Association between CDK4/6 inhibitors and drug-related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System.
Go M; Noguchi Y; Masuda R; Asano H; Kimura M; Usami E; Yoshimura T
Int J Cancer; 2024 Apr; ():. PubMed ID: 38619193
[TBL] [Abstract][Full Text] [Related]
2. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
3. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association.
Marcianò A; Guzzo GM; Peditto M; Picone A; Oteri G
Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33353034
[TBL] [Abstract][Full Text] [Related]
4. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS).
Ahdi HS; Wichelmann TA; Pandravada S; Ehrenpreis ED
BMC Pharmacol Toxicol; 2023 Mar; 24(1):15. PubMed ID: 36879299
[TBL] [Abstract][Full Text] [Related]
5. Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer.
Senín LD; Pancorbo DM; Garcés MYR; Santos-Rubio MD; Calero JB
Curr Oncol; 2024 Jan; 31(1):250-259. PubMed ID: 38248101
[TBL] [Abstract][Full Text] [Related]
6. Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study.
Ding H; Xu W; Dai M; Li S; Xin W; Tong Y; He C; Mi X; Zhan Z; Fang L
Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38753541
[TBL] [Abstract][Full Text] [Related]
7. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments.
Nawa H; Niimura T; Yagi K; Goda M; Zamami Y; Ishizawa K
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1402. PubMed ID: 33939324
[TBL] [Abstract][Full Text] [Related]
9. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
10. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
11. A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases.
Takeda T; Sugimoto S; Matsumoto J; Iwata N; Nakamoto A; Ozaki AF; Hamano H; Ariyoshi N; Zamami Y
Int J Clin Pharm; 2024 Apr; 46(2):536-541. PubMed ID: 38240964
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
Breast Cancer Res Treat; 2021 Feb; 186(1):219-227. PubMed ID: 33150548
[TBL] [Abstract][Full Text] [Related]
13. Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System.
Martins V; Jesus M; Pereira L; Monteiro C; Duarte AP; Morgado M
Pharmaceuticals (Basel); 2023 Sep; 16(10):. PubMed ID: 37895811
[TBL] [Abstract][Full Text] [Related]
14. The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels.
Nakatsukasa H; Takahashi M; Takahashi K; Takashima T; Asano Y; Morisaki T; Kashiwagi S; Noda S; Nakamura Y
Biol Pharm Bull; 2022; 45(10):1476-1481. PubMed ID: 36184505
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib.
Kikuchi M; Tanaka Y; Yokota M; Nishimiya H; Katoh H; Sengoku N; Kosaka Y
Biomed Rep; 2019 Dec; 11(6):253-256. PubMed ID: 31798870
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals.
Neha R; Beulah E; Anusha B; Vasista S; Stephy C; Subeesh V
Int J Clin Pharm; 2020 Apr; 42(2):721-727. PubMed ID: 32270377
[TBL] [Abstract][Full Text] [Related]
17. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network.
She Y; Guo Z; Zhai Q; Liu J; Du Q; Zhang Z
Front Pharmacol; 2024; 15():1378090. PubMed ID: 38633610
[TBL] [Abstract][Full Text] [Related]
19. Successful continuance of CDK4/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report.
Ozawa Y; Fujimiya T; Shimada A; Okazawa A; Kusano J; Yamamoto R; Hyasashi S
Anticancer Drugs; 2024 Jan; 35(1):89-92. PubMed ID: 37578747
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring in breast cancer therapy - LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum.
Habler K; Kalla AS; Rychlik M; Vogeser M; Teupser D
J Pharm Biomed Anal; 2023 Feb; 225():115211. PubMed ID: 36603395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
